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Approximately 22 million Africans have poor vision at distance and 101 million have poor 
near vision or presbyopia. The main causes are the easily treatable cataract and refractive 
































Background: To assess prevalence and causes of vision loss in Sub-Saharan Africa in 2015, 
compared to prior years, and to estimate expected values for 2020.  
Methods:  A systematic review and meta-analysis assessed the prevalence of blindness 
(presenting visual acuity<3/60 in the better eye), moderate and severe vision impairment (MSVI; 
presenting visual acuity <6/18 but ≥3/60) and mild vision impairment (MVI; presenting visual 
acuity <6/12 and ≥6/18); and also near vision impairment (>N5 or N8 in the presence of normal 
distance vision) in Sub-Saharan Africa (SSA) for 1990, 2010, 2015, and 2020.  
Results:  In SSA age-standardized prevalence of blindness, MSVI and MVI in 2015 were 0.40% 
(80% uncertainty interval (UI): 0.15 -0.71),1.65% (80% UI: 0.73 - 2.75) and 1.48% (80% UI: 0.49 
- 2.77), respectively, for males and 0.49% (80% UI: 0.18 - 0.89), 1.97% (80% UI: 0.84 - 3.33) 
and 1.71% (80% UI: 0.56 - 3.21), for females, constituting a significant decrease since 2010 for 
both genders.  There were an estimated 4.28 million blind individuals and 17.36 million 
individuals with MSVI; 101.08 million individuals were estimated to have near vision loss due to 
presbyopia. Cataract was the most common cause of blindness (41.62%), whereas uncorrected 
refractive error (48.52%) was the most common cause of MSVI. Sub-Saharan West Africa had 
the highest proportion of blindness (1.21% [80% UI:0.47 - 2.10] men and 1.28% [0.49 - 2.28] 
women) and MSVI (4.20% [2.05 - 6.71] men and 4.45% [2.10 - 7.22] women) compared to the 
other SSA subregions.  
Conclusions:  Cataract and uncorrected refractive error, two of the major causes of blindness 
and vision impairment, are reversible with treatment and thus promising targets to alleviate 












Nearly 30% of those in the World’s Multidimensional Poverty Index (MPI) live in sub-Saharan 
Africa (SSA).1 Sub-Saharan Africa has some of the lowest levels of infrastructure investment in 
the world. Health and eye health mirrors these deficits.  However, there are also indications that 
there have been reductions in poverty. In terms of poverty dynamics, of the 19 SSA countries 
for which Alkire and Housseiniwe (2014)2 presented time-series data (2008 or later), 17 
countries had statistically significant reductions in multidimensional poverty. This reduction in 
poverty may impact health and change the spectrum of disease in Africa, including the 
prevalence of vision impairment and blindness. These secular trends highlight the need to 
determine the corresponding temporal trends of blindness and vision impairment.  
 
Efforts to address eye health needs at a global level such as VISION 2020: Right to Sight, 
Universal Eye Health: A global action plan 2014 – 2019 (GAP)3 adopted by World Health 
Organization Member States at the World Health Assembly in 2013 and similar efforts, aim to 
reduce vision impairment and blindness. Achieving the targets of these efforts, such as reducing 
the prevalence of avoidable vision impairment by 25% from 2010 to 2019 as with GAP,3 requires 
epidemiological data—both to aid the planning of programs and to monitor the success and 
achievements of these campaigns/efforts. Furthermore, such data are critical for advocacy 
efforts to place eye health on the radar of governments and other influential parties. 
 
Generating evidence for eye health planning/assessment is a particularly difficult task for SSA 
given the paucity of population-based studies in many parts thereof. We previously published 
the temporal trends from 1990-2010 and the sub-regional variations based on available data at 
that time.4 In 2010, 16.6 million people had MSVI and 4.8 million people were blind in Africa, 
and there has been an increase in the absolute numbers affected since 1990. However, there 
has been a significant reduction in prevalence of blindness and vision impairment from 1990 to 
2010 with the estimated age-standardised prevalence of blindness declining from 1.9% in 1990 
to 1.3% in 2010, while MSVI decreased from 5.3% in 1990 to 4.0%  in  2010. Taking into 
account the additional population-based studies that were subsequently completed, here we 
present the temporal trends from 1980 to 2015 derived from a systematic review and meta-
analysis of population-based datasets submitted to the Global Vision Database relevant to Sub-
Saharan Africa vision impairment and blindness. In addition, we present the functional 
presbyopia prevalence, which was not done previously and highlights a significant vision 
impairment challenge and unmet need in the region. These estimates are especially important 
as the World Health Organization (WHO) is in the process of presenting a World Report which 





The methodology for the prevalence estimates for vision impairment and blindness—including 
the method of data identification, access, and extraction—has previously been described in 
detail and published in full elsewhere.5,-7 Here, we present the methodology most pertinent to 
this report.  
We estimated 1990-2015 trends in vision impairment prevalence and their uncertainties, by age 
and gender, for 188 countries in the 21 Global Burden of Disease (GBD) regions, using data 
from the Global Vision Database.8 The sub-Saharan Africa super-region consists of the regions 
of Central Africa, East Africa, Southern Africa, and West Africa. The distribution of countries 
within these regions is presented in Table 1.  
Using definitions and an analytical framework similar to that of Stevens et al,9 we developed 
statistical models to estimate the prevalence of two of the core categories of vision impairment: 
blindness (presenting visual acuity worse than 3/60) and a combined Moderate and Severe 
grouping called MSVI (presenting visual acuity worse than 6/18 to 3/60 inclusive).9 
We included distance and near vision impairment data from relevant population-based studies.  
These studies were identified through a systematic review which included studies published 
between 1980 and 2014 and unpublished data identified by members of the Vision Loss Expert 
Group of the Global Burden of Disease Study. 
For the statistical analysis, our model is based on the age-specific prevalence of vision 
impairment for 5-year age intervals. In cases where studies reported the prevalence of vision 
impairment for a wider age group - such as all ages or adults over 50 years - we converted 
these to 5-year age groups as follows. We fit two universal age patterns, one for the prevalence 
of blindness and one for the prevalence of MSVI, meta-analyzing from aggregated studies that 
reported prevalence for the narrower age groups. We fitted two hierarchical Bayesian logistic 
regressions to estimate vision impairment prevalence over time - by age group, gender and 
country - one model each for each vision impairment group.10 We modeled hierarchical linear 
trends over time, allowing for region-specific trends in prevalence of vision impairment for each 
of the seven world regions, including SSA.  Prevalence estimates were reported as posterior 
means along with 80% posterior uncertainty intervals (UI). We calculated trends, with 
uncertainty intervals, of age-standardized vision impairment by calculating the difference 
between the 1990 and 2015 age-standardized prevalences. We applied our model to forecast 
the prevalence of blindness and MSVI into the future (2020 and 2050). We calculated trends, 
with uncertainty intervals, of age-standardized vision impairment by calculating the difference 
between the 1990 and 2015 age-standardized prevalence.  
We estimated the prevalence of functional presbyopia (near vision impairment due to 
uncorrected presbyopia), from studies where presbyopia was defined as presenting near vision 
worse than N6 or N8 at 40cm regardless of distance refractive status. We only included data 
from those people whose best-corrected visual acuity was 6/12 (20/40) or better, so as to avoid 
double counting those with both distance and near vision impairment associated with non-
refractive causes. We developed a similar model to the main model used for blindness and 
MSVI.  
Our model relies on health status and education as covariates. Since it is impossible to predict 
how these will evolve decades into the future, we extrapolated these covariates to the year 2020 
and then held them constant to 2050 in order to forecast prevalence of blindness and MSVI into 
the future.  As our model gives estimates of crude prevalence for country-years we relied on the 
United Nations Population Division’s (UNPOP) forecasts to 2050 to derive crude numbers 
affected and age-standardized prevalence.  
We estimated the proportions of overall vision impairment attributable to cataract, glaucoma, 
age-related macular degeneration, diabetic retinopathy, corneal opacity, trachoma, uncorrected 




Of the total of 288 studies included in the global meta-analysis Sub-Saharan Africa contributed 
69 studies. Since the last global meta-analysis that produced estimates for 2010,4 16 new 
studies were added from countries in Sub-Saharan Africa (Table 1). We considered the age-
standardised prevalence estimates by gender and sub regions for the SSA region for all ages as 
well as for adults 50 years and older. In 2015, the age-standardised prevalence for all ages and 
genders was 1.05% (0.39-1.87) for blindness and 3.74% (1.70-6.10) for MSVI, 3.0 % (1.06-
5.48) for mild vision impairment and 49.37 (34.75-63.96) for presbyopia (Table 2). SSA 
contributes 9.53% of the global prevalence of presbyopia and 10.05% in 2020, a slight increase 
from current levels.This is lesser than for blindness and MSVI probably due to the younger age 
of the population. Women had a slightly higher prevalence for all categories (Blindness, MSVI 
and Mild VI) in the all age age-standardised prevalence. The age-standardised prevalence in 
blindness and MSVI decreased from 1.9% and 5.3% in 2010 to 1.05% and 3.74 % respectively 
in 2015.  
The age-standardised prevalence of blindness in the 50 years and older age group was higher 
than the age-standardised prevalence for all ages, 4.82% (2.17-7.98) for males and 5.03% 
(2.28-8.33) for females (Table 3). These values are lower than the age-standardised blindness 
prevalence for males and females in 2010 which were 5.0% (4.0%-5.8%) and 5.5% (4.4%-
6.4%), respectively. A similar trend was evident for MSVI. In 2015, West Africa had the highest 
age-standardised blindness prevalence and MSVI with Southern Africa the lowest, akin to the 
2010 results.4 
In contrast, given anticipated population growth and aging, the absolute number of people with 
blindness, MSVI and Mild VI is predicted to increase in SSA from 2015 to 2020 (Table 4). SSA 
mirrors the global trend. In 2015, the estimated number of blind people is 4.28 million people 
(1.54-7.68) but by 2020 we forecast this will increase to 4.74 million (1.65-8.63).  The number of 
people with MSVI is expected to increase from 17.36 million (7.53-29.16) to 19.67 million (5.34-
33.56). Based on these figures, in 2015 and 2020 respectively, SSA comprises 11.88% and 
11.61% of world blindness. For MSVI, Africa in 2015 and 2020 Africa contributes or will 
contribute 8.03% and 8.29% to the world MSVI respectively, a small increase in the proportion. 
Functional presbyopia is predicted to increase from 106.36 million (72.21-141.38) in 2015 to 
125.55 million (84.97-166.58) in 2020. 
The proportion of blindness and MSVI by cause for all ages in 2015 is presented in Tables 5 
and 6, respectively. As in 1990, cataract continues to be the main contributor to blindness in the 
SSA region and this trend is forecast to remain through 2020. The category of ‘other’ conditions 
is the next main cause of blindness, followed by glaucoma, refractive error, age-related macular 
degeneration, corneal opacity, trachoma and then diabetic retinopathy. By 2020 the percentage 
of blindness due to glaucoma in SSA will be 13.47% (4.30%-25.35%) compared to the global 
prevalence of 8.27% (2.64-15.76).   
Uncorrected refractive error was the main cause of MSVI in 2015, as also was the case in 1990 
and which is projected to continue as such to 2020.  Cataract is the next main cause of MSVI 
followed by other conditions, age-related macular degeneration, glaucoma, trachoma, corneal 
opacity and diabetic retinopathy, respectively.  
The data show great variation in crude and age-standardised blindness prevalence for the 
countries in the region (Figure 1). Among adults aged 50 years and older, the crude prevalence 
of blindness for both males and females was the lowest in Equatorial Guinea and the highest in 
Ethiopia, while age-standardised prevalence was lowest in Gabon and highest in Ethiopia.  
Among adults aged 50 years and older as well as for all ages, the crude prevalence of MSVI for 
both males and females was the lowest in Botswana and highest in Eritrea (Figure 2). 
 
DISCUSSION 
The series of population-based studies that were conducted in Africa since the last review in 
2010, have provided greater granularity of the data.  Still, these studies represent focal 
geographies within countries and primarily focus on the 50 years and older age group, which in 
turn is a limitation of our meta-analysis of the studies. There is still a lack of nationally 
representative population-based studies in Africa.  
As a result of its young population age structure, SSA currently has one of the lower absolute 
burdens of vision impairment. However, Sub-Saharan Africa has the highest age-standardized 
prevalence of vision impairment in the world, suggesting the burden of vision impairment will 
become the highest in the world once the demographic transition takes place. The proportion of 
people aged 50 years and older who have vision impairment (presenting) exceeds 25% in the 
region. Interventions to prevent future blindness, including investment in infrastructure and 
training of eye care practitioners, are indicated now to forestall or at least mitigate this incoming 
tidal wave of vision impairment. 
Cataract remains the most important cause of blindness in 2015 and the second most important 
cause of MSVI. The African age-standardised cataract prevalence has been consistently higher 
than the global prevalence from 1990 to 2015 and we project it to continue thus through 2020. 
Furthermore, the number of cataract blind persons has increased from 2010 to 2015 and is 
projected to increase further by 2020 with population growth and aging, despite the 
considerable focus on cataract services in national programs and often at the expense of the 
overall eye health services development. These considerations demonstrate that a significant 
effort is needed to ensure the promotion, availability, affordability, accessibility and sustainability 
of cataract surgical services in SSA. Cataract surgical rates (CSR) of around 500 
operations/million population/annum are common in many countries whereas the WHO has 
stated that 2000/million population/annum is need to achieve elimination of cataract blindness.12 
13 14 Despite significant focus on cataract blindness and vision impairment, this limited progress 
can be attributed to the lack of human resources that plagues SSA, as well as population growth 
and aging. The number of ophthalmologists and other eye care practitioners remain low in most 
countries; 15 unless this is addressed, the prevalence of cataract will remain a significant 
contributing factor to blindness and vision impairment. Strategies to increase surgical output 
also need to be urgently addressed. Sufficient surgical infrastructure such as operating theatres 
or access to operating theatres as well as surgical equipment and maintenance support for this 
infrastructure need to be implemented as it is a prerequisite to increased surgical output.16 
Sustainable economic models also are prerequisite to sustained surgical and clinical care output 
and a sufficiently vibrant eye care profession to sustain the work. 
In terms of uncorrected refractive error, the data from 1990 to 2015 and projection to 2020 
depict a lower prevalence for SSA than the global prevalence, reflecting the lower surge in 
myopia rates in Africa compared to the rest of the world.17 However, myopia is projected to 
increase globally, affecting 50% of the world population by 2050, and this increase in 
prevalence likely will occur in Africa as well. While myopia primarily will affect the MSVI 
prevalence data, the projected 20% of myopia consisting of high myopia, with its potentially 
blinding sequelae, 17 also may affect the prevalence of blindness. Unless refractive services are 
expanded to a corresponding degree, the gains made in reducing the prevalence of blindness 
and vision impairment through avoidable blindness prevention efforts in Africa will be reversed 
through likely increased incidence of myopia. There are some promising signs over the last 10 
years with the development of new optometry schools in Mozambique, Malawi, Eritrea, Ethiopia, 
Cameroon, Gambia and Mali. However, in general the number of training programs for 
refractionists or optometrists in Africa is insufficient, and this human resource remains a 
significant barrier. Furthermore, access and affordability of spectacles still remains a significant 
barrier for many, which needs to be addressed to lower the burden of uncorrected refractive 
error and functional presbyopia. As a result of these challenges, while there has been an 
incremental increase in refractive services, it has not been of the scale that is needed to 
substantially reduce the leading cause of vision impairment in SSA. Investing in refractive 
services also likely would help address the challenges that Africa has in terms of screening, 
detecting and diagnosing other eye diseases such as glaucoma, diabetic retinopathy and age-
related macular degeneration. These diseases usually do not manifest symptoms until their 
advanced stages, hence the importance of refractive services that can motivate the population 
to undergo eye examinations to provide early detection and prevention. These refractive 
services need satisfactory training programs and effective referral pathways for onward hospital 
management of patients.  
Africa has a disproportionate prevalence of global blindness and vision impairment attributable 
to glaucoma relative to its population and age structure. The prevalence of glaucoma-
attributable blindness has increased from 1990 to 2015 and is projected to increase in 2020. It is 
not surprising as the resources (specialists, clinicians, drugs and equipment) to manage 
glaucoma are limited.18 19 Addressing glaucoma by focusing on the disease specifically, to the 
degree that has been possible, has not yielded the outcomes needed thus far. Other strategies 
should be explored and validated including adopting a team approach to glaucoma and 
integrating glaucoma screening, diagnosis and management into the process of providing eye 
exams either as part of a comprehensive eye exam or within refractive error or cataract 
services.  
An immense investment in the management of trachoma in Africa has been associated with a 
significant decline in prevalence. The proportion of blindness and vision impairment due to 
trachoma has progressively reduced from 1990 to 2015 and is projected to reduce even further 
by 2020. This trend can be attributed to the significant global efforts in implementing programs 
and raising funds to address trachoma in SSA. In 1998, the World Health Assembly committed 
to the Global Elimination of Trachoma as a cause of blindness and the WHO Alliance set up to 
spearhead these efforts set the year 2020 as the target date for elimination.20 According to 
Courtwright et al (2018) “Prospects for achieving elimination are more promising. Global 
mapping of trachoma is almost complete, most trachoma endemic countries have clear and 
practical plans for implementation and elimination, and governments, donors and partners have 
significantly increased their support for elimination.”21 
It was previously assumed that age-related macular degeneration (AMD) is not a major concern 
in Africa; this perception was influenced by the lack of population based studies in Africa that 
adequately quantified AMD.22  However, our study indicates that the global trend of AMD 
causing a progressively greater share of blindness is similar in Africa. In fact, in 2015, the 
proportion of blindness due to AMD was marginally higher than the global prevalence of 
blindness due to AMD. This trend is projected to continue in 2020 and as the demographic 
transition occurs in SSA, the impact is expected to be even greater.  
Diabetes mellitus is no longer confined to rich nations and is increasing everywhere.23  The 
proportion of blindness and vision impairment due to diabetic retinopathy mirrors this reality. 
Blindness and vision impairment due to diabetic retinopathy in SSA, while lower than the global 
prevalence, has shown a steady increase in prevalence which is projected to continue to 2020. 
This trajectory poses a major challenge for eye care in Africa, as the capacity to provide regular 
retinal exams and monitoring is limited. It is critical that strategies such as the training of other 
cadres besides ophthalmologists (e.g., diabetic nurses) and/or telemedicine programs to 
monitor diabetic patients be considered. In countries such as South Africa and Nigeria, 
graduating optometrists have the ability to conduct dilated fundus exams and should be 
considered as part of the diabetic management team. Telemedicine and the advances in low 
cost digital imaging techniques also offer an opportunity for ophthalmologists to reach more 
patients by leading team-based approaches to the problem.  
The gender disparities in access to eye care and the prevalences of blindness and vision 
impairment, is a challenge in Africa. The gender disparities in the age-standardised prevalences 
of blindness and MSVI evident in 2010 remains manifest in the 2015 data. In 2010, the disparity 
was 0.2% for blindness and MSVI;4 in 2015 the difference was 0.05 % for blindness and 0.2% 
for MSVI. While the improvement in the blindness data is encouraging, focus on services 
addressing the eye care needs of women is needed to eliminate the gap in blindness as well as 
MSVI.  
The limitations in the methodology of our study have been published elsewhere.24 In our 
previous review of the 1990-2010 data, we identified a gap in the literature in terms of the 
measurement of the burden of blindness and vision impairment due to onchocerciasis as well as 
the shortage of nationally representative studies.  These limitations are relevant to this review 
as well.4 The fact that our method largely reflects Rapid Assessment of Avoidable Blindness 
(RAAB) studies, which report cause-specific data for a limited number of diseases as a 
pragmatic strategy to simplify conduct of population-based studies, means that these studies 
prioritize cataract and refractive error as causes and underestimate other diseases that may co-
exist. This limitation has particular relevance in SSA, where the second most important cause of 
blindness is the “other” category instead of uncorrected refractive error as in much of the world. 
The RAAB studies also focus on those aged 50 years and older which results in a paucity of 
data from younger age groups in this region. 
An adaptation of RAAB and other large-scale population-based studies need to be considered 
as the category “other conditions” features significantly in the prevalence of blindness (second 
highest cause) and vision impairment (third highest cause). The range of diseases that make up 
this category needs to be delineated, as lack of knowledge of the nature of the problem limits 
capacity to address these conditions. While doing so may place greater training, financial and 
human resource burden on data collection, the high burden of the “other conditions” category 
makes it imperative that the diseases in that category be defined and addressed.  
Cataract and uncorrected refractive error constitute more than 50% of blindness and vision 
impairment in 2015 and are projected to do so in 2020 as well. Continued and increased 
investment to address these conditions has the potential to significantly reduce the prevalence 
of blindness and vision impairment in SSA.  However, the increase in prevalence of glaucoma, 
AMD and diabetic retinopathy raise the need for comprehensive eye care services to enable 
these conditions to be diagnosed and managed. This is a particularly huge challenge for SSA as 
the human resources and infrastructure to provide such services is limited. However, given the 
limited progress in targeting cataract blindness by both governments and civil society 
organisations on average in SSA, a systems approach that provides comprehensive eye health, 
articulation with other sectors in health care such as diabetic clinics, and the appropriate referral 
pathways may be what is needed.4 Sustainable economic models for such services, such as 
have been demonstrated in other parts of the world, will be needed. Programs to alleviate 
blindness “backlogs” should bear in mind the potential impact of widespread free services on 
future development of sustainable approaches to the delivery of services that alleviate vision 
impairment; subsidized programs may be preferable to free programs.  
Despite the progress made in reducing the blindness and vision impairment prevalence, much 
of this has been achieved through the efforts in addressing conditions such as trachoma which 
are more amenable to a campaign type of approach and may truly be eliminated, as opposed to 
endemic diseases which cause most blindness. As the African population ages and uncorrected 
refractive error, AMD and diabetic retinopathy prevalence increases, innovative sustainable 
approaches need to be adopted. The emergence of technological solutions can assist in this 
regard but in addition comprehensive team approach to eye care will be needed likely including 
task shifting and appropriate referral pathways within team-based service delivery. Still, task 
shifting programs should avoid disincentivizing medical school graduates from training in 
ophthalmology; access to higher level training and robust career opportunities will be needed at 
all levels of eye care professions to retain the human resources needed to deal with the 
endemic causes of blindness on an ongoing basis. 
 
The proportions of blindness from cataract, glaucoma, uncorrected refractive error and diabetic 
retinopathy are expected to increase by 2020. A comprehensive strategy from government, civil 
society and private sector that is aimed at addressing eye care needs can make a significant 
impact in terms of reducing the overall prevalence of blindness. However, given the current 
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Angola, Central African Republic, Congo*, Democratic Republic of the 
Congo, Equatorial Guinea, Gabon  
East Africa 
Burundi*, Comoros, Djibouti, Eritrea*, Ethiopia*, Kenya*, Madagascar, 
Malawi*, Mauritius, Mozambique*, Rwanda*, Seychelles, Somalia, 
Sudan*, Tanzania*, Uganda*, Zambia*  
Southern Africa Botswana*, Lesotho, Namibia, South Africa*, Swaziland, Zimbabwe*  
West Africa 
Benin*, Bukina Faso, Cameroon*, Cape Verde*, Chad, Cote d'Ivoire, 
Gambia*, Ghana*, Guinea, Guinea-Bissau, Liberia, Mali*, Mauritania*, 
Niger, Nigeria*, Senegal, Sierra Leone*, Sao Tome and Principe, Togo 
    
*Those for which data were available are marked with an asterisk. 





TABLE 2. Crude and age-standardised prevalence (%) of blindness and moderate and severe 
vision impairment (MSVI), mild vision impairment (VI) and presbyopia in 2015 in Sub Saharan 
Africa (all ages); 80% uncertainty intervals are given in brackets 
 
  Blind MSVI Mild VI Presbyopia 
Crude prevalence         
Males 0.40 (0.15 - 0.71) 1.65 (0.73 - 2.75) 1.48 (0.49 - 2.77)   
Females 0.49 (0.18 - 0.89) 1.97 (0.84 - 3.33) 1.71 (0.56 - 3.21)   





        
Males 1.03 (0.39 - 1.81) 3.64 (1.71 - 5.94) 2.94 (1.05 - 5.34)   
Females 1.08 (0.40 - 1.93) 3.84 (1.72 - 6.37) 3.06 (1.07 - 5.61)   
All  1.06 (0.4-1.87)  3.74(1.72-6.12) 3.00 ( 1.06-5.48) 49.37 (34.75 - 63.96) 
 
  
TABLE 3. Age-standardised prevalence of blindness and moderate and severe vision 
impairment (MSVI) and mild vision impairment (VI) by gender and region comparing adults 50 
years and older with all ages, for 2015 in Sub-Saharan Africa; 80% uncertainty intervals in 
brackets 
                         50+ 
       
All ages 
                         Men Women Men Women 
Regio
n 
Blind MSVI Mild 
VI 

































































































































































































































































































TABLE 4. Age-standardised prevalence of blindness and moderate and severe vision 
impairment (MSVI) and mild vision impairment (VI) and presbyopia by gender and region 
comparing adults 50 years and older with all ages, for 2015 in Sub-Saharan Africa; 80% 
uncertainty intervals in brackets 
Regio
n 
Blind MSVI Mild Presbyopia 










































































































































































TABLE 5. Percentage of blindness by cause for all ages in 1990, 2010, 2015 and 2020. 
80% uncertainty intervals are given in brackets.* 
 
1990 





















0.96 (0.95 - 
0.98) 












































1.69 (1.65 - 
1.73) 

































































2.81 (2.69 - 
2.94) 
19.40 (7.40 - 
33.86) 
2010 




















0.51 (0.49 - 
0.53) 




















9.82 (8.99 - 
10.66) 





















0.89 (0.83 - 
0.95) 




















5.51 (5.00 - 
6.03) 











































1.56 (1.39 - 
1.72) 
24.02 (9.24 - 
41.76) 
2015 



















0.27 (0.25 - 
0.29) 




















7.02 (6.13 - 
7.95) 





















0.51 (0.44 - 
0.58) 




















3.43 (2.91 - 
4.01) 












































0.98 (0.80 - 
1.16) 
25.46 (9.82 - 
44.20) 
2020 



















0.08 (0.06 - 
0.10) 




















4.00 (3.10 - 
4.95) 





















0.11 (0.04 - 
0.19) 




















1.34 (0.99 - 
1.89) 
















































*URE=uncorrected refractive error; AMD=age-related macular degeneration; DR=diabetic retinopathy; 
Other=a disease not specified by the other categories. 
 
  
TABLE 6.  Percentage of moderate and severe vision impairment (MSVI) by cause for all 









































































 (1.20 - 
6.90) 
10.22 






















































































9.91 (3.12 - 
18.78) 



































































































































































































































































































































































9.91 (2.67 - 
19.93) 
Sub-Saharan 
Africa, 
Southern 
49.20 
(46.69 - 
51.35) 
26.13 
(17.81 - 
34.98) 
4.07 
(1.09 - 
8.34) 
7.48 
(1.55 - 
16.17) 
2.20 
(0.31 - 
4.90) 
1.78 
(0.20 - 
4.00) 
0.06 
(0.01 - 
0.12) 
10.66 (2.89 
- 21.43) 
Sub-Saharan 
Africa, West 
48.38 
(45.47 - 
50.90) 
33.40 
(23.83 - 
43.27) 
3.29 
(0.95 - 
6.54) 
2.53 
(0.46 - 
5.48) 
0.47 
(0.06 - 
0.98) 
1.97 
(0.23 - 
4.35) 
0.89 
(0.63 - 
1.37) 
11.25 (3.03 
- 22.61) 
Sub-Saharan 
Africa 
48.61 
(45,69- 
51.16) 
31.25 
(22.10- 
40.75) 
3.45 
(0.98- 
6.92) 
3.86 
(0.76- 
8.34) 
0.91 
(0.12- 
1.97) 
1.88 
(0.22- 
4.18) 
1.13 
(0.89- 
1.47) 
10.81 
(2.91- 
21.73) 
World 53.88 
(50.69 - 
56.58) 
23.74 
(16.88 - 
30.89) 
1.92 
(0.52 - 
3.91) 
3.82 
(0.77 - 
8.29) 
1.43 
(0.18 - 
3.32) 
1.23 
(0.15 - 
2.73) 
0.22 
(0.16 - 
0.37) 
13.76 (4.42 
- 25.92) 
 
 
 
